To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Nanoparticle Albumin-Bound Paclitaxel Approved in Australia for Metastatic Breast Cancer URL: http://www.pslgroup.com/dg/22EEB6.htm Doctor's Guide October 16, 2008
NEW YORK -- October 16, 2008 -- The Therapeutic Goods Administration (TGA) in Australia has approved nanoparticle albumin-bound paclitaxel (Abraxane) 100-mg powder for injection for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. The approval was based on the results of a phase 3 clinical trial which demonstrated that nanoparticle albumin-bound paclitaxel doubled the response rate and significantly prolonged progression-free survival and overall survival compared with paclitaxel (Taxol) in the approved indication. The most reported serious adverse events associated with nanoparticle albumin-bound paclitaxel in the study included neutropenia, anaemia, infections, sensory neuropathy, nausea, vomiting, and myalgia/arthralgia. Other common adverse reactions included anaemia, asthenia, diarrhoea, ocular/visual disturbances, fluid retention, alopecia, hepatic dysfunction, mucositis, and renal dysfunction. SOURCE: Abraxis --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.